News

Biogen to Settle Kickbacks Lawsuit for $900 Million

September 28, 2022

Biogen has agreed to pay $900 million to settle federal and state claims that it paid kickbacks to physicians to encourage them to prescribe its drugs.

Novel Imaging Approach Reveals Key Details About Rare Eye Disease

September 28, 2022

A combination of eye imaging techniques and adaptive optics has revealed key details of choroideremia.

Actylis Debuts as an Integrated Global Specialty Ingredients Manufacturing and Sourcing Provider

September 28, 2022

Actylis combines Aceto and its 10 acquired specialists into a singular global brand.

Novo Nordisk and Octagon Therapeutics Enter Inflammatory Disease Research Collaboration

September 28, 2022

The collaboration will use Octagon’s functional target discovery approach and novel chemistry strategy in disease areas in which Novo Nordisk has specific expertise.

Alcami Adds Solid-State Characterization Capabilities to North Carolina Laboratory

September 28, 2022

The dedicated solid-state research and development suite is designed to promote discovery of novel polymorph, salt, and cocrystal forms.

Pfizer to Supply up to 6 Million PAXLOVID Treatment Courses for Low-and-Middle-Income Countries

September 27, 2022

Pfizer is set to supply global fund up to 6 million treatment courses of its COVID-19 oral treatment, PAXLOVID, for low-and-middle-income countries.

EC Approves Vabysmo for Two Leading Causes of Vision Loss

September 27, 2022

EC has approved Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss.

Roquette Acquires Indian Excipient Manufacturer

September 27, 2022

Roquette’s acquisition of Crest Cellulose is designed to reinforce its presence in India and other countries in Asia.

Chris Lockwood to Lead Technical Services at Aprecia

September 27, 2022

Aprecia has hired Chris Lockwood as head of technical services at its Ohio facility.

Congress Slated to Reauthorize User Fees Without FDA “Improvements”

September 23, 2022

Legislative leaders are looking to approve a bare-bones measure to fund FDA operations as part of a short-term government funding bill.